Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe-Reference-Cited by-同舟云学术

Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe

Published:2017-01 Issue:1 Volume:38 Page:139-146
ISSN:1531-7129
Container-title:Otology & Neurotology
language:en
Short-container-title:

Author:

Mercado-Pimentel Melania Ester,Miller Craig,Rolph Daniela N.,Villalobos Edrick F.,Dunn Allison M.,Mohan Prithvi M.,Igarashi Suzu,Liu Xiangdang,Yrun-Duffy Macken,Patel Neal K.,Read Cecilia M.,Francis Ross H.,Lane Adelina Isabella,Murugesh Swaroop,Jacob Abraham

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Clinical Neurology,Sensory Systems,Otorhinolaryngology

Reference48 articles.

1. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2;Rouleau;Nature,1993

2. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis);Martuza;N Engl J Med,1988

3. NF2 mutations in secretory and other rare variants of meningiomas;Hartmann;Brain Pathol,2006

4. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes;Evans;J Med Genet,2006

5. Emerging functions of p21-activated kinases in human cancer cells;Kumar;J Cell Physiol,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma;PLOS ONE;2024-07-31

2. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis;Oncogene;2024-02-09

3. Simultaneous Inhibition of PI3K and PAK in Preclinical Models of Neurofibromatosis Type 2-related Schwannomatosis;2023-10-16

4. PAK4-relevant proliferation reduced by cell autophagy via p53/mTOR/p-AKT signaling;Translational Cancer Research;2023-03

5. Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects;Frontiers in Oncology;2021-09-27